The UK’s inaugural medical technology (medtech) strategy has been released. It sets out how the health and social care system can reliably access safe, effective, and innovative medical technologies. The strategy builds on and supports the Life Sciences Vision to help secure the position of the UK as a global science superpower.
The strategic priorities have been developed in conjunction with partners across industry, government, and the health and care system to identify the priority areas:
- ensuring resilience and continuity of supply of medtech products
- supporting innovation and encouraging thriving, dynamic markets
- developing enabling infrastructure
- specific focuses on key issues and markets
Action on these priority areas will support delivery of the strategy’s vision for the right product, at the right price, and in the right place, and, the continued delivery of high-quality care, outstanding patient safety and excellent patient outcomes in a way that makes best use of taxpayer money.
BIVDA welcomes first strategy for Medical Technology from the Government.
BIVDA’s Chief Executive, Doris-Ann Williams MBE said “BIVDA saw the creation of the MedTech Directorate as a valuable and pragmatic step for our industry, in vitro diagnostics (IVDs) are a crucial part of the much wider MedTech sector”.
“We welcome the Medical Technology Strategy which is comprehensive and covers all the aspects that our industry faces in delivering world class diagnostic testing to the NHS, including market access and regulation”.
“We are committed to working closely with look forward to working closely with the MedTech Directorate to support delivery of this Strategy”.
You can read the strategy in full here.
